A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Condition(s) studied
Investigational drug(s) / intervention(s)
Drug: 5 mg BGM0504 Administered SC: Drug: BGM0504 Administered SC
Drug: : 10 mg BGM0504 Administered SC: Drug: BGM0504 Administered SC
Drug: Placebo Administered SC: Drug: Placebo Administered SC
Study summary
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of BGM0504 in patients with type 2 diabetes (T2D) with poor glycemic control only through diet and exercise.
The main purpose is to evaluate the clinical efficacy of BGM0504 injection monotherapy for 32 weeks compared with placebo in Chinese patients with type 2 diabetes with poor glycemic control only through diet and exercise, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.
Eligibility
Primary outcome measure(s)
- Change From Baseline in Hemoglobin A1c (HbA1c) — Week 0 to Week 32
Change from baseline in HbA1c after 32 weeks of treatment.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Peking University People's Hospital | Beijing | Beijing Municipality |
More BrightGene Bio-Medical Technology Co., Ltd. trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06716203 on ClinicalTrials.gov ↗ ← All trials in China